Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Amit Sanyal, MD: A Clinician’s Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Varsha Gandhi, PhD, on Ibrutinib

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

David A. Hyman, MD, JD, on Inclusive Shared Savings

Nov

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Varsha Gandhi, PhD, on Ibrutinib

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

David A. Hyman, MD, JD, on Inclusive Shared Savings

Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women

Large AI Breast Cancer Screening Trial Increases Detection Rate

Addition of Durvalumab to BCG After TURBT for BCG-Naive, High-Risk NMIBC

Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With Acute Myeloid Leukemia

Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies